The EIC Accelerator provides blended grant‑equity financing for deep‑tech startups, matching the venture’s need for non‑dilutive capital and later equity. The programme’s EU focus aligns with the founder’s plan to operate in Île‑de‑France, and its emphasis on innovative biotech/AI solutions fits the drug‑resistance prediction technology.